Literature DB >> 16189143

Molecular pathology of ataxia telangiectasia.

A M R Taylor1, P J Byrd.   

Abstract

Ataxia telangiectasia (A-T) is one of a group of autosomal recessive cerebellar ataxias. Presentation is usually by the age of 2 years and ataxia of both upper and lower limbs develops, such that by early teenage most patients require a wheelchair for mobility. Speech and eye movement are also affected. Other important features are t(7;14) translocations, immunodeficiency, a high serum alpha fetoprotein concentration, growth retardation, telangiectasia-most noticeably on the bulbar conjunctiva-and a very high risk of developing a lymphoid tumour. Patients also show an increased sensitivity to ionising radiation. The classic form of A-T results from the presence of two truncating ATM mutations, leading to total loss of the ATM protein, a protein kinase. Importantly, A-T shows clinical heterogeneity, including milder forms where neurological progression may be slower or of later onset. In these cases there is a correlation between the preservation of neurological function, decreased radiosensitivity, and the degree of retained ATM protein kinase activity. Considerable scope remains for understanding the progress of the disorder in relation to the types of ATM mutation present.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189143      PMCID: PMC1770730          DOI: 10.1136/jcp.2005.026062

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  73 in total

1.  AT-tributable risks?

Authors:  D T Bishop; J Hopper
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

2.  Unusual features in the inheritance of ataxia telangiectasia.

Authors:  C G Woods; S E Bundey; A M Taylor
Journal:  Hum Genet       Date:  1990-05       Impact factor: 4.132

3.  A family showing no evidence of linkage between the ataxia telangiectasia gene and chromosome 11q22-23.

Authors:  D Hernandez; C M McConville; M Stacey; C G Woods; M M Brown; P Shutt; G Rysiecki; A M Taylor
Journal:  J Med Genet       Date:  1993-02       Impact factor: 6.318

4.  Mutations associated with variant phenotypes in ataxia-telangiectasia.

Authors:  C M McConville; T Stankovic; P J Byrd; G M McGuire; Q Y Yao; G G Lennox; M R Taylor
Journal:  Am J Hum Genet       Date:  1996-08       Impact factor: 11.025

5.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.

Authors:  T Stankovic; P Weber; G Stewart; T Bedenham; J Murray; P J Byrd; P A Moss; A M Taylor
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 6.  Leukemia and lymphoma in ataxia telangiectasia.

Authors:  A M Taylor; J A Metcalfe; J Thick; Y F Mak
Journal:  Blood       Date:  1996-01-15       Impact factor: 22.113

7.  Ataxia without telangiectasia masquerading as benign hereditary chorea.

Authors:  C Klein; G K Wenning; N P Quinn; C D Marsden
Journal:  Mov Disord       Date:  1996-03       Impact factor: 10.338

Review 8.  Cancer risks in A-T heterozygotes.

Authors:  D F Easton
Journal:  Int J Radiat Biol       Date:  1994-12       Impact factor: 2.694

9.  Incidence of cancer in 161 families affected by ataxia-telangiectasia.

Authors:  M Swift; D Morrell; R B Massey; C L Chase
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

10.  Predominance of null mutations in ataxia-telangiectasia.

Authors:  S Gilad; R Khosravi; D Shkedy; T Uziel; Y Ziv; K Savitsky; G Rotman; S Smith; L Chessa; T J Jorgensen; R Harnik; M Frydman; O Sanal; S Portnoi; Z Goldwicz; N G Jaspers; R A Gatti; G Lenoir; M F Lavin; K Tatsumi; R D Wegner; Y Shiloh; A Bar-Shira
Journal:  Hum Mol Genet       Date:  1996-04       Impact factor: 6.150

View more
  59 in total

1.  Homozygosity for c 6325T>G transition in the ATM gene causes an atypical, late-onset variant form of ataxia-telangiectasia.

Authors:  Gabriella Silvestri; Marcella Masciullo; Maria Piane; Camilla Savio; Anna Modoni; Massimo Santoro; Luciana Chessa
Journal:  J Neurol       Date:  2010-05-18       Impact factor: 4.849

2.  Characterisation of ATM mutations in Slavic Ataxia telangiectasia patients.

Authors:  Jana Soukupova; Petr Pohlreich; Eva Seemanova
Journal:  Neuromolecular Med       Date:  2011-08-11       Impact factor: 3.843

3.  ATM regulates Mre11-dependent DNA end-degradation and microhomology-mediated end joining.

Authors:  Elias A Rahal; Leigh A Henricksen; Yuling Li; R Scott Williams; John A Tainer; Kathleen Dixon
Journal:  Cell Cycle       Date:  2010-07-12       Impact factor: 4.534

4.  A novel mouse model for ataxia-telangiectasia with a N-terminal mutation displays a behavioral defect and a low incidence of lymphoma but no increased oxidative burden.

Authors:  Andrew Campbell; Brittany Krupp; Jared Bushman; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Hum Mol Genet       Date:  2015-08-26       Impact factor: 6.150

5.  The relative biological effectiveness of densely ionizing heavy-ion radiation for inducing ocular cataracts in wild type versus mice heterozygous for the ATM gene.

Authors:  Eric J Hall; Basil V Worgul; Lubomir Smilenov; Carl D Elliston; David J Brenner
Journal:  Radiat Environ Biophys       Date:  2006-06-24       Impact factor: 1.925

Review 6.  Assessing cancer risks of low-dose radiation.

Authors:  Leon Mullenders; Mike Atkinson; Herwig Paretzke; Laure Sabatier; Simon Bouffler
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

Review 7.  An update on inherited ataxias.

Authors:  Tanja Schmitz-Hübsch; Thomas Klockgether
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

8.  Compromized DNA repair as a basis for identification of cancer radiotherapy patients with extreme radiosensitivity.

Authors:  Pavel Lobachevsky; Trevor Leong; Patricia Daly; Jai Smith; Nickala Best; Jonathan Tomaszewski; Ella R Thompson; Na Li; Ian G Campbell; Roger F Martin; Olga A Martin
Journal:  Cancer Lett       Date:  2016-09-28       Impact factor: 8.679

9.  ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors:  Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

10.  ATM mediates repression of DNA end-degradation in an ATP-dependent manner.

Authors:  Elias A Rahal; Leigh A Henricksen; Yuling Li; John J Turchi; Katherine S Pawelczak; Kathleen Dixon
Journal:  DNA Repair (Amst)       Date:  2008-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.